Liquid Chromatography coupled Mass Spectrometer

神经病理学（目标1-4）、神经肿瘤学（目标5-6）和普通病理学（目标7-8）部门将通过使用待购买的质谱仪来实现以下目标：MGMT（O 6-甲基鸟嘌呤-DNA-甲基转移酶）甲基化胶质母细胞瘤中预测性生物标志物的鉴定。福尔马林固定和石蜡包埋组织的蛋白质组学分析以及新鲜冷冻组织中磷蛋白的方案的开发和实施-开发脑肿瘤特异性蛋白质图谱，旨在基于蛋白质组的肿瘤分类和识别新的诊断生物标志物-开发基于质谱的测定方法，用于测定脑肿瘤相关信号转导途径活性-IDH突变型胶质瘤中胶质瘤起始和进展的分子机制-解读对靶向治疗的抗性-肝癌中基于蛋白质的亚型和标志物鉴定-成像基质辅助激光解吸电离中的蛋白质鉴定-战斗时间，MALDI-TOF数据集

The following aims will be pursued by the departments of Neuropathology (Aims 1-4), Neurooncology (aims 5-6) and general Pathology (aims 7-8) by employing a mass spectrometer to be purchased:Identification of predictive biomarkers in MGMT (O6-Methylguanin-DNA-Methyltransferase) methylated glioblastomas.- Development and Implementation of protocols for proteomic analysis of formalin fixed and paraffin embedded tissues and for phosphor proteins in fresh frozen tissues - Development of a brain tumor specific protein atlas aiming at proteome based tumor classification and at identification of novel diagnostic biomarkers- Development of a mass spectrometry based assays for determination of brain tumor relevant signal transduction pathway activity- Molecular mechanisms of glioma initiation and progression in IDH mutant glioma- Deciphering of resistance towards targeted therapy- Protein based subtyping and marker identification in liver cancer- Protein identification in Imaging matrix-assisted laser desorption ionization - time of fight, MALDI-TOF data sets